Biopharma’s next big bets: The science, deals and strategies shaping 2027

Biopharma will enter 2027 with more capital in motion, more pressure on pipelines and more places to place a bet. Pharma companies are looking to China for assets, investors are backing larger biotech rounds, the IPO market is reopening and a looming patent cliff is raising the stakes for dealmaking. At the same time, obesity pipelines are moving beyond first-generation GLP-1s, psychedelics are nearing a commercial test and new direct-to-consumer models are challenging the industry’s traditional approach to reaching patients.

At Fierce JPM Week 2027, leaders from across pharma, biotech and investment will examine where the industry is putting its biggest bets and what it will take for them to pay off. From new therapeutic modalities and cross-border licensing to megadeals, public markets and U.S. manufacturing, the conversations will focus on the choices shaping the next phase of biopharma.